Table 5. Down-regulated mir-15a predicted poor survival in newly diagnosed MM patients receiving both thalidomide and bortezomib based therapy.
Subgroups | Median PFS (months) | P value | Median OS (months) | P value |
---|---|---|---|---|
Arm A | 0.046 | 0.016 | ||
Mir-15a low level (n = 8) | 15.0 | 16.0 | ||
Mir-15a high level (n = 38) | 47.0 | 55.5 | ||
Arm B | 0.003 | 0.002 | ||
Mir-15a low level (n = 8) | 13.5 | 16.0 | ||
Mir-15a high level (n = 32) | 29.0 | Not reached |